Abstract: A method of digital measuring the color of fabrics based on digital camera, includes: making plain fabric samples; obtaining ground-truth color of plain fabrics using a spectrophotometer; capturing a raw format digital image of the plain fabrics using the digital camera and extracting raw camera responses of the plain fabrics; capturing a raw format digital image of a target fabric and extracting the raw camera responses of a ROI in the target fabric; calculating a Euclidean distance and a similarity coefficient between the raw camera responses of the ROI in the target fabric and the plain fabrics; normalizing the Euclidean distance and the similarity coefficient; calculating a weighting coefficient of each color data of the plain fabrics based on the normalized Euclidean distance and similarity coefficient; weighting every color data of plain fabrics with a corresponding weighting coefficient; and summing the weighted color data of the plain fabrics.

Abstract: A sanding tool includes a baseplate assembly, a housing assembly, a drive mechanism, and a fan assembly. The baseplate assembly includes a baseplate. The housing assembly includes a body housing. The housing assembly further includes a functional housing, where a hollow cavity is formed in the functional housing, the functional housing is provided with an inlet and an outlet that communicate with the hollow cavity, the inlet communicates with a dust removal channel of the sanding tool, the outlet is configured to discharge gas in the cavity, and the fan assembly is used for forming a dust removal air path moving towards the inlet. A ratio of an area of a projection of the functional housing on the baseplate to an area of the baseplate is greater than or equal to 0.15 and less than or equal to 0.95.

Abstract: A scanner assembly (100) may include a housing (102) having abase (104) forming a cavity with an open top. Further, the housing (102) may include a platen (106) having a top surface (108) and a bottom surface (110). The bottom surface (110) may be attached to the base (104) around a periphery of the cavity. Furthermore, the housing (102) may include a bezel (112) adhered to the top surface of the platen (106) to cover an edge region of the top surface (108). The bezel (112) may include a bottom surface (114) having an inclined notch (116). Furthermore, the scanner assembly (100) may include a scanner module (118) movably disposed in the housing (102) below the platen (106). The scanner module (118) may be in an optical communication with the inclined notch (116) to detect a home position.

Abstract: A method and apparatus for determining the sealability of an oil & gas well sealant fluid, whereby a cylindrical cell assembly capable of withstanding high temperature and high pressure with an electromagnetic heater positioned radially outside the cell body while partly filled with said sealant fluid. A minor-leak assembly in connection to said cylindrical cell assembly allows said sealant fluid to continuously flow through a leak sample at a desired differential pressure, and the residual fluid is drained into said cell by a cycling pipeline system. The real-time pressure may be recorded to transmitted to a control system comprised of data acquisition and control units so as to monitor and measure the sealability of fluid in the downhole minor leaks.

Abstract: A scheduling system includes a receiving system and a transfer system. The receiving system receives a carrier carrying a biological sample. The transfer system transfers the sample carrier between biochemical reaction platform and detection platform, so that a sample in the sample carrier performs a biochemical reaction on the biochemical reaction platform, and a signal from the reacted sample can be detected on the detection platform. The present disclosure further provides a scheduling method, a scheduling control system, a biochemical analysis system and device, and a computer-readable storage medium. The present disclosure improves a degree of automation of sample carrier scheduling, and realizes simultaneous analysis of multiple sample carriers to improve a testing throughput.

Abstract: Provided in the present invention is a small molecule compound, which is characterized in that it is a compound or a stereoisomer, geometric isomer, tautomer, racemate, hydrate, solvate, metabolite, and pharmaceutically acceptable salt or prodrug of the compound as represented by the following structural formula: formula (I). The small molecule compound of the present invention is applicable as a highly efficient and specific JAK kinase inhibitor, specifically a Tyk2 inhibitor and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor.

Abstract: A touch panel having dummy pattern is provided, including a first metal nanowire layer and a second metal nanowire layer. The first metal nanowire layer includes first electrode wires, first axial wires connected to the first electrode wires, and first dummy patterns. The second metal nanowire layer includes a plurality of second electrode wires and a plurality of second axial wires connected to the second electrode wires. The first dummy patterns are electrically insulated and deposited outside the first electrode wires and the first axial wires, and each of the first dummy patterns comprises a plurality of first etching areas extending along the first and second directions. The first dummy patterns do not expose the first etching areas along the first direction at a vertical projection area of a part where each of the second axial wires alone exists, so that the electrode pattern is difficult to observe.

Abstract: The present disclosure belongs to the field of application of protein, and relates to use of a protein in predicting properties of a drug. The drug comprises pesticides, human drugs and veterinary drugs, and the protein is applied in the following steps: preparing a 0.02 M phosphate buffer solution with pH value of 7.4; dissolving and diluting a protein solution with the prepared buffer solution according to a signal value to obtain a protein diluent; mixing the prepared protein diluent with the drug to be tested in a molar ratio of 1: (1-300) to obtain a mixed solution to be tested, and predicting the drug properties by using fluorescence spectrum, synchronous fluorescence, three-dimensional fluorescence, circular dichroism spectrum, UV-Vis absorption spectrum, linear spectrum or band spectrum.

Abstract: The present invention relates to a pyrimido[5,4-b]pyrrolizin compound represented by general formula I, an optical isomer thereof, a preparation method therefor, a pharmaceutical composition containing same, and a use thereof. The compound according to the present invention has good inhibitory activity on the kinase BTK at both the molecular level and the cellular level. Meanwhile, the compound also has good anti-tumor activity and pharmacokinetic properties in vivo.

Abstract: A sanding tool includes a machine body, a power supply, a base plate assembly, a drive mechanism, and a control mechanism. The machine body includes a casing. The base plate assembly includes a base plate. The drive mechanism is disposed in the casing and includes a motor and an output shaft, the motor has a motor shaft rotating around a first axis, the output shaft rotates around a second axis, and the output shaft transmits power to the base plate assembly. The control mechanism is electrically connected to the motor and configured to control the sanding tool to operate. The first axis and the second axis form an included angle and are not in the same plane. A battery pack and the motor are disposed on two sides of the output shaft.

Abstract: A compound compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, amino, alkylamino, dialkylamino, CF3, or hydroxyl; A is selected from the group consisting of a bond, C?O, —SO2—, —(C?O)NR0—, and —(CRaRb)q—, where R0 is H or C1-C4 alkyl, and Ra and Rb are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, etc.

Abstract: Methods of treatment as Janus Kinase inhibitors containing the compound of the invention having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N; A is selected from the group consisting of a bond and C?O; R1 is C3-C6 cycloalkyl, wherein said cycloalkyl is further optionally substituted with one or more halo; R2 is hydrogen; R3 is hydrogen; R4 is monocyclic heteroaryl wherein said heteroaryl is optionally substituted with one or more C1-C6 alkyl; and, R5 is hydrogen; and, j is 0 or 1.

Abstract: A compound having the structure: or an acceptable salt thereof, wherein X is N or CR, where R is hydrogen, alkyl, etc.; A is selected from the group consisting of a bond, C?O, —SO2—, etc.; A? is selected from the group consisting of a bond, C?O, etc.; Z is —(CH2)h— or a bond, etc.; R1 and R1? are independently selected from the group consisting of hydrogen, alkyl, etc.; R2 is selected from hydrogen, alkyl, etc.; R3 is selected from the group consisting of hydrogen, and amino; R4 is monocyclic or bicyclic, etc.; R5 is independently selected from hydrogen, alkyl, etc.; h, j, k, m, n and q are integers as defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: A method for treating cancer includes the steps of: administering to a subject an effective amount of zero valent iron (ZVI) nanoparticles and an effective amount of at least one resistance modulating agent. The shell of each of the ZVI nanoparticles includes gold (Au). The resistance modulating agent includes inducers of programmed cell death, such as erastin, sulfasalazine, sorafenib, buthionine sulfoximine, Ras selective lethal 3 (RSL-3), altretamine, and FIN56. The resistance modulating agent can induce ferroptosis, promote lipid peroxidation, block NADP(H) supply, or suppress metabolism of polyunsaturated fatty acids. Alternatively, the resistance modulating agent can suppress expression of at least one of GSR, AKR1C1, AKR1C3, AKR1B1, AKR1B10 and KYNU genes or promote expression of at least one of ACSL4, ZEB1 and NNMT genes. A method for improving efficacy of a cancer treatment using the ZVI nanoparticles and another method for treating cancer are also provided.

Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Abstract: A compound compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, amino, alkylamino, dialkylamino, CF3, or hydroxyl; A is selected from the group consisting of a bond, C?O, —SO2—, —(C?O)NR0—, and —(CRaRb)q—, where R0 is H or C1-C4 alkyl, and Ra and Rb are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, etc.

Abstract: Provided in the present invention are a substituted amino six-membered nitric heterocyclic ring compound and a preparation and use thereof. In particular, provided in the present invention is a compound as shown by general formula (I) below, wherein the definition of each group is as described in the description. The compound of the present invention has an excellent tyrosine kinase inhibitory activity, and can thus be used to prepare a series of medicines for treating diseases related to tyrosine kinase inhibitory activity.

Abstract: Rotor of a gas turbine engines having a rotor hub and a plurality of blades extending from the rotor hub, wherein each blade has a full-span forward sweep along a leading edge of the blade that starts at an airfoil root of the blade at the hub and extends to a blade tip, wherein a sweep of a blade is a percentage of a root axial chord length of the respective blade.

Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, wherein X is N or CR, where R is hydrogen, deuterium, C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, aryl, heteroaryl, aryl(C1-C6 alkyl), CN, amino, alkylamino, dialkylamino, CF3, or hydroxyl; A is selected from the group consisting of a bond, C?O, —SO2—, —(C?O)NR0—, and —(CRaRb)q—, where R0 is H or C1-C4 alkyl, and Ra and Rb are independently hydrogen, deuterium, C1-C6 alkyl, C3-C6 cycloalkyl, aryl, aryl(C1-C6 alkyl), heteroaryl, (C1-C6 alkyl)heteroaryl, etc.